Maxim Group analyst Anthony Vendetti maintained a Buy rating on Helius Medical Technologies (HSDT – Research Report) yesterday and set a price target of $1.00. The company’s shares closed yesterday at $0.15.
According to TipRanks, Vendetti is an analyst with an average return of -2.2% and a 32.87% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Cutera, Nephros, and Nuwellis.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Helius Medical Technologies with a $1.00 average price target.
See today’s best-performing stocks on TipRanks >>
HSDT market cap is currently $4.26M and has a P/E ratio of -0.11.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Helius Medical Technologies, Inc. operates as a medical technology company, which engages in the development of products for the treatment of neurological symptoms caused by disease and trauma. It focuses on licensing and acquiring platform technologies that amplify the brain’s ability to heal itself. The company was founded in 2014 and is headquartered in Newtown, PA.
Read More on HSDT:
- Helius Medical Technologies, Inc. Reports First Quarter 2023 Financial Results
- HSDT Upcoming Earnings Report: What to Expect?
- Helius Medical showcasing PoNS device at AAN annual meeting
- Helius Medical Technologies to Spotlight Expanded Authorizations for its PoNS Device at 2023 American Academy of Neurology Annual Meeting, Booth 1685
- Helius Medical Technologies, Inc. Announces Distribution of Series B Preferred Stock to Holders of its Class A Common Stock Intended to Facilitate a Reverse Stock Split, if Necessary
